MiNK Therapeutics (NASDAQ:INKT) Lowered to “Sell” Rating by Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

INKT has been the subject of a number of other reports. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Performance

Shares of INKT stock opened at $12.40 on Friday. The stock has a market capitalization of $58.16 million, a price-to-earnings ratio of -4.09 and a beta of 0.34. The company’s 50-day simple moving average is $12.00 and its 200-day simple moving average is $14.05. MiNK Therapeutics has a one year low of $4.56 and a one year high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.21. As a group, research analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.